The Filing Desk

Kymera Therapeutics vs Protagonist Therapeutics

Kymera Therapeutics KYMR · Protagonist Therapeutics PTGX · Biotechnology

Protagonist Therapeutics reported revenue of $46 million in fiscal 2025, 1.2 times Kymera Therapeutics' $39 million in fiscal 2025. Kymera Therapeutics' revenue fell 16.7% in its latest year, and Protagonist Therapeutics' fell 89.4%. Kymera Therapeutics had an operating margin of -891.1%, against -343.6% at Protagonist Therapeutics. Free cash flow was −$234 million at Kymera Therapeutics and $56 million at Protagonist Therapeutics.

Side by side

Kymera TherapeuticsProtagonist Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$39M$46M
Revenue growth−16.7%−89.4%
Revenue growth a year, last 5 years2.9%10.0%
Gross margin0.0%—
Operating margin−891.1%−343.6%
Net margin−794.0%−282.8%
Free cash flow−$234M$56M
Free cash flow margin−597.6%121.9%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count12.6%−2.3%
Last close$127.57$130.95
P/E at the last close—27.8×
Insider trades, last 12 monthsbought $172.5 million, sold $461.2 millionsold $79.4 million
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Kymera TherapeuticsProtagonist Therapeutics
Operating margin
Percent of revenue
Kymera TherapeuticsProtagonist Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Kymera TherapeuticsProtagonist Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Kymera Therapeutics and Protagonist Therapeutics pages.